Clinical trial data key to personalization of treatment decisions
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
We push the boundaries of finance to solve complex problems and fuel progress in the world through the MIT finance ecosystem – a unique global network of people, programs, research, and partnerships.
By
Since its inception, the program has helped launch 70 thriving companies
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Here, leadership is not a title or a person. It’s a process. We begin with self-awareness, then combine science-based frameworks, personalized coaching, and practical applications to develop leaders.
Leadership at MIT is not a title or a person. It’s a process. We begin with self-awareness and combine science-based frameworks, personalized coaching, and practical applications to develop leaders.
By
Wharton’s Ethan Mollick and MIT Sloan’s Bill Aulet discuss the ways generative artificial intelligence is remaking the competitive landscape of entrepreneurship.
We are a small but mighty team dedicated to helping MIT students develop as dynamic leaders equipped to collaborate with others to solve the world’s most pressing problems.
Twelve teams of students and postdocs across the MIT community presented innovative startup ideas with potential for real-world impact.